These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 21591300)

  • 21. Cost-effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer.
    Hatoum HT; Crawford ED; Nielsen SK; Lin SJ; Marshall DC
    Expert Rev Pharmacoecon Outcomes Res; 2013 Apr; 13(2):261-70. PubMed ID: 23570437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The potential for normal tissue dose reduction with neoadjuvant hormonal therapy in conformal treatment planning for stage C prostate cancer.
    Yang FE; Chen GT; Ray P; Vaida F; Chiru P; Hamilton RJ; Spelbring D; Abellera M; Vijayakumar S
    Int J Radiat Oncol Biol Phys; 1995 Dec; 33(5):1009-17. PubMed ID: 7493827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Penile length changes in men treated with androgen suppression plus radiation therapy for local or locally advanced prostate cancer.
    Haliloglu A; Baltaci S; Yaman O
    J Urol; 2007 Jan; 177(1):128-30. PubMed ID: 17162022
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant hormone therapy: the Canadian trials.
    Klotz L; Gleave M; Goldenberg SL
    Mol Urol; 2000; 4(3):233-7;discussion 239. PubMed ID: 11062379
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radiation plus hormone therapy reduces prostate cancer mortality.
    Cancer Discov; 2014 Apr; 4(4):OF1. PubMed ID: 24706660
    [No Abstract]   [Full Text] [Related]  

  • 26. External beam radiation therapy for clinically localized prostate cancer: when and how we optimize with concurrent hormonal deprivation.
    Koontz BF; Lee WR
    Arch Esp Urol; 2011 Oct; 64(8):858-64. PubMed ID: 22052767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized trials in early prostate cancer. II: hormone therapy and radiotherapy for locally advanced disease: a question is still unanswered. MRC PR07 Trial Management Group.
    Mason MD; Brewster S; Moffat LE; Kirkbride P; Cowan RA; Malone P; Sydes M; Parmar MK
    Clin Oncol (R Coll Radiol); 2000; 12(4):215-6. PubMed ID: 11005685
    [No Abstract]   [Full Text] [Related]  

  • 28. Evaluating the use of early hormonal therapy in patients with localised or locally advanced prostate cancer.
    Kaisary AV
    Prostate Cancer Prostatic Dis; 2005; 8(2):140-51. PubMed ID: 15852051
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primary hormonal treatment in localized and locally advanced prostate cancer: effectiveness and survival predictive factors.
    Utomo NB; Mochtar CA; Umbas R
    Acta Med Indones; 2012 Jan; 44(1):10-5. PubMed ID: 22451179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Hormonal treatment of cancer of the prostate: review and present status].
    Ganzer R; Wieland WF; Bach T; Rössler W; Blana A
    Dtsch Med Wochenschr; 2007 Jan; 132(4):161-6. PubMed ID: 17230333
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
    Miyake H; Hara I; Eto H
    BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Hepatic encephalopathy induced by flutamide administered for the treatment of prostatic cancer].
    Patel H; Rhee E; Zimmern PE
    J Urol (Paris); 1996; 102(3):123-5. PubMed ID: 9091557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of hormone therapy on acute radiotherapy toxicity in the treatment of prostate cancer.
    Jani AB; Gratzle J; Myers M
    Prostate Cancer Prostatic Dis; 2005; 8(3):224-8. PubMed ID: 15983626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant hormonal treatment with radiotherapy for locally advanced prostate cancer.
    Bolla M
    Eur Urol; 1999; 35 Suppl 1():23-5; discussion 26. PubMed ID: 10081699
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
    Ho AY; Burri RJ; Cesaretti JA; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):16-22. PubMed ID: 19289266
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Re: The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
    Gardiner RA; Nicol DL; Green HJ; Yaxley J; Watson R; Mactaggart P; Headley BC; Swanson C; Pakenham KI
    J Urol; 2004 Aug; 172(2):774; author reply 774-5. PubMed ID: 15247782
    [No Abstract]   [Full Text] [Related]  

  • 38. Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.
    Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1439-44. PubMed ID: 19540066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Re: A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy.
    Pickles T
    J Urol; 2005 Dec; 174(6):2423-4; author reply 2424. PubMed ID: 16280866
    [No Abstract]   [Full Text] [Related]  

  • 40. Carcinoma of the prostate: neoadjuvant hormonotherapy followed by radiotherapy.
    Scalliet P
    Acta Urol Belg; 1996 May; 64(2):63-4. PubMed ID: 8701815
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.